Home
Live Updates
Lenvatinib-Pembrolizumab Combo Misses Goal in First-Line HCC Trial : comparemela.com
Lenvatinib-Pembrolizumab Combo Misses Goal in First-Line HCC Trial
Numerical advantages in OS, PFS fall short of statistical significance
Related Keywords
Barcelona ,
Comunidad Autonoma De Cataluna ,
Spain ,
New York ,
United States ,
Hong Kong ,
American ,
Landon Chan ,
Josep Llovet ,
Stephen Chan ,
Icahn School Of Medicine At Mount Sinai ,
Tisch Cancer Institute ,
Hong Kong Cancer Institute ,
Icahn School ,
Mount Sinai ,
New York City ,
Medpage Today ,
American Association ,
Hong Kong Cancer ,
Barcelona Clinic Liver Cancer ,
Managing Editor ,
comparemela.com © 2020. All Rights Reserved.